Roche told patient groups it is ending two Huntington’s disease development programs, including the Ionis-partnered antisense drug tominersen (Phase 2) after efficacy disappointment and its early-stage asset RG6496 after an animal dosing-safety signal. The company said the programs’ discontinuations are independent, data-driven decisions, while reporting that tominersen met safety and biomarker endpoints but not disease-severity objectives. Roche said its Huntington’s disease gene therapy program RG6662 remains ongoing. The move further trims a category of antisense-based approaches competing for disease modification goals in Huntington’s.